Michael Shih is the founder of NeoPhore. NeoPhore has raised $40M in total funding. Latest round: Series B. Based in Altrincham, Cheshire, United Kingdom.
Michael Shih is the Chief Executive Officer of NeoPhore, a drug-discovery company focused on DNA mismatch repair / neoantigen-related cancer therapeutics. He was appointed CEO in December 2024 following the company's oversubscribed Series B financing.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide